Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Ontology highlight
ABSTRACT: The purposes of this study are to determine whether administering escalating doses of cetuximab in patients with no early skin toxicity could delay the progression of disease in a significant proportion of patients and to study the molecular signatures of response.
DISEASE(S): K-ras Wild Type Metastatic Colorectal Cancer,Colorectal Cancer,Colorectal Neoplasms,Colorectal Cancer Metastatic
PROVIDER: 2098880 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA